Tirzepatide · side effects
Tirzepatide side effects: common, serious, and compounded-specific
The GI and serious side-effect profile of tirzepatide from approved labeling, plus compounded-specific risks.
The most common tirzepatide side effects are gastrointestinal — nausea, diarrhea, vomiting, and constipation — and are usually dose-related and most prominent during dose increases. Serious risks include a boxed warning for thyroid C-cell tumors (based on rodial studies) and rarer pancreatitis, gallbladder disease, and kidney injury from dehydration. These profiles come from the approved product; compounded tirzepatide carries the same pharmacology plus added uncertainty about ingredient identity and purity.
Common adverse events
Most common adverse events with approved tirzepatide (SURMOUNT-1-era labeling, % of patients) — approved labeled dosing; compounded/microdose products are not separately characterized
The chart reflects approved-product labeling. Gastrointestinal effects dominate and are usually manageable, but they are also the most common reason people stop treatment. Dehydration from vomiting or diarrhea is the mechanism behind several of the more serious downstream problems, which is why hydration and prompt clinical contact matter.
Tirzepatide's gastrointestinal rates in trials were broadly similar to or somewhat lower than semaglutide's at the reported doses — nausea around 29%, diarrhea near 23%, constipation around 17% — but its dual GIP/GLP-1 mechanism is newer and its long-term adverse-event picture is less mature. A tirzepatide-specific caution is severe gastrointestinal disease: it has not been adequately studied in severe gastroparesis, so clinicians are careful in people with significant GI motility problems.
Like semaglutide, tirzepatide has a long half-life and is escalated slowly under the approved label, so GI effects tend to track dose increases. Because tirzepatide reaches higher milligram maintenance strengths and engages two incretin receptors, some people experience a different balance of appetite suppression and GI effects than they did on a single-agonist drug — one reason it is sometimes considered after a semaglutide plateau, and a reason self-directed dosing of a compounded version is risky.
Serious risks and warnings
| Risk | Notes |
|---|---|
| Boxed warning: thyroid C-cell tumors | Based on rodent studies; contraindicated with personal/family history of medullary thyroid carcinoma or MEN 2. |
| Pancreatitis | Discontinue if suspected; evaluate for acute pancreatitis. |
| Gallbladder disease | Cholelithiasis has been reported; rapid weight loss is itself a risk factor. |
| Hypoglycemia | Mainly when combined with insulin or a sulfonylurea. |
| Acute kidney injury | Usually from dehydration due to vomiting/diarrhea. |
| Severe gastrointestinal disease | Not studied in severe gastroparesis; caution advised. |
What the evidence shows
- GI side effects are common with tirzepatide and are dose-related.
- Serious risks (boxed thyroid warning, pancreatitis, gallbladder, kidney) are documented for the approved product.
What the evidence does not show
- That a microdose is free of side effects — lower doses reduce but do not eliminate risk.
- That compounded products are quality-assured like the approved drug — they are not FDA reviewed.
Frequently asked questions
What are the most common tirzepatide side effects?
Nausea, diarrhea, vomiting, and constipation, usually dose-related and worst during increases.
Does tirzepatide have a boxed warning?
Yes — a boxed warning for thyroid C-cell tumors based on rodent studies; it is contraindicated with a personal or family history of medullary thyroid carcinoma or MEN 2.
Are microdose side effects lower?
Lower doses generally cause fewer GI effects, but risk is not zero and serious warnings still apply.
If you are managing side effects, see what to do after side effects.
Not medical advice. This page is consumer education, not medical advice, and does not recommend a dose, product, or provider. Compounded medications are not FDA approved. Talk with a licensed clinician about your situation.